Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.47% 0.16% 349.49M 57844.33
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0.18% 52.00% 152.96M Upgrade

Basic Info

Investment Strategy
The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Unaligned
Fund Owner Firm Name iShares
Prospectus Benchmark Index
NYSE FactSet Glb Gnmcs&Imm Bio NR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Alan Mason 2.31 yrs
Amy Whitelaw 2.31 yrs
Greg Savage 2.31 yrs
Jennifer Hsui 2.31 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 15
152.96M
-4.465B Category Low
6.183B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of September 30, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of October 26, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2014
2015
2016
2017
2018
2019
2020
YTD
--
--
--
--
--
--
54.29%
8.63%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
19.15%
--
--
--
--
--
--
51.52%
-8.38%
36.34%
1.73%
-22.90%
22.28%
-0.19%
18.65%
25.66%
7.67%
14.75%
1.51%
-12.90%
50.15%
-1.23%
34.45%
67.26%
0.33%
--
--
--
--
--
--
65.01%
6.63%
As of October 26, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (10-26-21) 0.18%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 23.66
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of October 25, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of October 25, 2021

Asset Allocation

As of October 25, 2021.
Type % Net % Long % Short
Cash 0.19% Upgrade Upgrade
Stock 99.81% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Moderna Inc 6.36% 345.74 -1.09%
Intellia Therapeutics Inc 5.44% 132.00 -1.16%
Merck KGaA
4.98% -- --
BioNTech SE ADR 4.75% 292.39 -0.86%
Evotec SE
4.46% -- --
Seagen Inc Ordinary Shares 4.43% 177.70 1.24%
Genmab A/S
4.27% -- --
Regeneron Pharmaceuticals Inc 4.20% 592.15 2.77%
Sarepta Therapeutics Inc 4.10% 77.99 -2.13%
BeiGene Ltd Ordinary Shares
4.08% -- --

Basic Info

Investment Strategy
The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Unaligned
Fund Owner Firm Name iShares
Prospectus Benchmark Index
NYSE FactSet Glb Gnmcs&Imm Bio NR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Alan Mason 2.31 yrs
Amy Whitelaw 2.31 yrs
Greg Savage 2.31 yrs
Jennifer Hsui 2.31 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (10-26-21) 0.18%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 23.66
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of October 25, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of October 25, 2021

Fund Details

Key Dates
Inception Date 6/11/2019
Last Annual Report Date 7/31/2021
Last Prospectus Date 12/1/2020
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No